VRP.L Share News (VRP)
VRP Share
VRP Share
VRP Share
VRP Share
VRP
VRP Share
VRP Broker
VRP Directors
VRP Financial
VRP
VRP Short
VRP
LONDON (Alliance News) - Clinical-stage biopharmaceutical company Verona Pharma PLC said on Thursday Chair David Ebsworth bought 26,300 shares for 56.30 pence each on Wednesday.Following in
Read more
(Sharecast News) - RSA Insurance Group: JP Morgan downgrades to neutral with a target price of 610p.
Read moreLONDON (Alliance News) - Shares in Verona Pharma PLC rose on Monday following positive data from part of a Phase Two clinical trial of a dry powder inhaler formulation of Verona's ensifentrine
Read moreLONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - LOSERS----------Paddy Power
Read moreLONDON (Alliance News) - Verona Pharma PLC on Monday said its phase two clinical trial of nebulized Ensifentrine did not meet its primary endpoint but did perform better than placebo.Shares
Read more(Sharecast News) - Verona Pharma shares were well into the red on Monday, after the clinical-stage biopharmaceutical company announced top-line data from its latest trial of RPL554, failing to reach its primary endpoint.
Read more(Sharecast News) - Clinical stage biopharmaceutical outfit Verona Pharma has been granted approval of the name Ensifentrine for its first-in-class, inhaled, dual inhibitor drug candidate RPL554 by the World Health Organisation.
Read more(Sharecast News) - Clinical-stage biopharmaceutical company Verona Pharma announced the initiation of a Phase 2 clinical trial to evaluate the pharmacokinetic (PK) profile, efficacy and safety of a dry powder inhaler (DPI) formulation of 'RPL554', in patients with moderate to severe chronic obstructive pulmonary disease (COPD), on Monday.
Read moreLONDON (Alliance News) - Verona Pharma PLC on Tuesday said its loss narrowed by two thirds in the third quarter of 2018 on increased finance income and reduced costs as it initiated a phase two of
Read moreLONDON (Alliance News) - Verona Pharma PLC said Wednesday it has completed the enrollment for its Phase 2 clinical trial evaluating the effect of nebulised RPL554 as an add-on to dual therapy in a
Read more(Sharecast News) - Clinical-stage biopharmaceutical company Verona Pharma turned in some positive data from its pre-clinical and Phase 2a trials on its potential cystic fibrosis treatment RPL554.
Read moreLONDON (Alliance News) - Verona Pharma PLC said Wednesday that it started the second phase of a clinical trial of its nebulized RPL554 drug for the treatment of patients with chronic obstructive 2
Read moreLONDON (Alliance News) - Stock prices in London are seen opening lower on Tuesday following Monday's UK bank holiday as Chinese exports recovered at a faster pace in April amid concerns the US
Read moreLONDON (Alliance News) - Verona Pharma PLC said Monday it has received positive top-line data from its phase 2b study for its proposed RPL554 treatment.RPL554 is a for
Read moreLONDON (Alliance News) - Verona Pharma PLC, a clinical-stage biopharmaceutical company, said Thursday that Chief Executive Officer Jan-Anders Karlsson purchased 3,250 ordinary
Read more
